Ocrelizumab reduces cortical and deep grey matter loss compared to the S1P-receptor modulator in multiple sclerosis.

Massimiliano CalabreseAgnese TamantiAngela PelosoStefano Ziccardi Maddalena GuandaliniMilena CalderoneMarco Castellaro Francesca Benedetta PizziniStefania MontemezziDamiano Marastoni Massimiliano Calabrese

Published in: Journal of neurology (2024)

When compared with FGL, patients receiving OCR showed greater suppression of focal MRI lesions accumulation and lower cortical and deep grey matter volume loss.

Keyphrases

multiple sclerosis
white matter
magnetic resonance imaging
contrast enhanced
diffusion weighted imaging